Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital (Q43746530)

26 November 2017

title

Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital (English)

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

15 October 2022

1 reference

R. F. Unzelman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1615973

15 October 2022

language of work or name

English

0 references

publication date

1 June 1992

1 reference

full work available at URL

26 November 2017

https://api.elsevier.com/content/article/PII:000293789291554N?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

https://api.elsevier.com/content/article/PII:000293789291554N?httpAccept=text/plain

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

American Journal of Obstetrics and Gynecology

15 October 2022

published in

1 reference

26 November 2017

volume

166

1 reference

26 November 2017

issue

6 Pt 1

1 reference

26 November 2017

page(s)

1663-71; discussion 1671-2

1 reference

26 November 2017

cites work

Cancer statistics, 1991

1

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.

15 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Nonparametric Estimation from Incomplete Observations

15 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

15 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma

15 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Current concepts in cancer: ovary--treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors.

15 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Predictive factors for long-term survival in patients with advanced ovarian cancer

15 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

15 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

15 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity

15 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Incidence of subclinical metastasis in stage I and II ovarian carcinoma

15 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Staging Laparotomy in Early Ovarian Cancer

15 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

15 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Pelvic and para-aortic lymphadenectomy in cancer of the ovary

15 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Reasons for incomplete surgical staging in early ovarian carcinoma

15 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Primary cytoreductive surgery for epithelial ovarian cancer

15 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma

15 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

15 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Predictability of the survival of patients with advanced ovarian cancer.

15 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Primary surgical therapy of ovarian cancer: how much and when

15 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

The impact of subspecialty training on the management of advanced ovarian cancer

15 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

15 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG))

15 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Management of epithelial ovarian neoplasms using a platinum-based regimen: a 10-year experience

15 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives

15 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Controversial aspects of cytoreductive surgery in epithelial ovarian cancer

15 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma

15 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Debulking surgery: Does it increase the quality of survival?

15 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Screening in ovarian cancer

15 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Primary surgical therapy of ovarian cancer: how much and when

15 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma

15 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

Failure of second-look laparotomy to influence survival in epithelial ovarian cancer

15 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0002-9378(92)91554-N

15 October 2022

Identifiers

1 reference

26 November 2017

1 reference